

ABBOTT LABORATORIES
Form 4
February 22, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
BIRD ROGER

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK, IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

ABBOTT LABORATORIES [ABT]

3. Date of Earliest Transaction (Month/Day/Year)

02/17/2017

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

Senior Vice President

6. Individual or Joint/Group Filing (Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
| | | | Code | V | Amount | (D) | Price |
| Common shares without par value | 02/17/2017 | | A | | 13,307 (1) | A | \$ 0 63,910 |
| Common shares without par value | 02/21/2017 | | F | | 727 | D | \$ 44.69 63,183 |
| Common shares without par value | 02/21/2017 | | S | | 219 | D | \$ 44.91 62,964 |

Edgar Filing: ABBOTT LABORATORIES - Form 4

| | | | | | | | |
|---------------------------------|------------|---|--------|---|------------|--------|---|
| Common shares without par value | 02/21/2017 | S | 100 | D | \$ 44.995 | 62,864 | D |
| Common shares without par value | 02/22/2017 | M | 11,030 | A | \$ 26.6973 | 73,894 | D |
| Common shares without par value | 02/22/2017 | M | 1,873 | A | \$ 26.1976 | 75,767 | D |
| Common shares without par value | 02/22/2017 | S | 9,936 | D | \$ 45.02 | 65,831 | D |
| Common shares without par value | 02/22/2017 | S | 700 | D | \$ 45.03 | 65,131 | D |
| Common shares without par value | 02/22/2017 | S | 100 | D | \$ 45.031 | 65,031 | D |
| Common shares without par value | 02/22/2017 | S | 1,500 | D | \$ 45.035 | 63,531 | D |
| Common shares without par value | 02/22/2017 | S | 400 | D | \$ 45.04 | 63,131 | D |
| Common shares without par value | 02/22/2017 | S | 100 | D | \$ 45.041 | 63,031 | D |
| Common shares without par value | 02/22/2017 | S | 167 | D | \$ 45.045 | 62,864 | D |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Edgar Filing: ABBOTT LABORATORIES - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Option (right to buy) ⁽²⁾ | \$ 44.4 | 02/17/2017 | | A | 92,032 | 02/17/2018 02/16/2027 | Common shares | 92,032 |
| Option (right to buy) ⁽³⁾ | \$ 26.6973 | 02/22/2017 | | M | 11,030 | 02/15/2011 02/14/2018 | Common shares | 11,030 |
| Option (right to buy) ⁽³⁾ | \$ 26.1976 | 02/22/2017 | | M | 1,873 | 03/31/2011 03/30/2018 | Common shares | 1,873 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|-----------------------|-------|
| | Director | 10% Owner | Officer | Other |
| BIRD ROGER 100 ABBOTT PARK ROAD ABBOTT PARK, IL 60064 | | | Senior Vice President | |

Signatures

John A. Berry, by power of attorney for Roger Bird
02/22/2017

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.

(2) Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,678 on 02/17/2018, 30,677 on 02/17/2019, and 30,677 on 02/17/2020.

(3) Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

The sale transactions on February 21, 2017, were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.